Ligand Pharma (LGND) Tops Q3 EPS by 6c, Offers FY20 and FY21 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St futures edge higher in countdown to Fed decision
- Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
- JPMorgan Downgrades Rapid7 (RPD) to Underweight
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Ligand Reports Third Quarter 2020 Financial Results
October 30, 2020 8:00 AM EDTConference Call with Slides Begins at 8:30 a.m. Eastern Time Today
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.
"Our business is performing very well across the board. We are pleased to be reporting strong third quarter financial results and foresee substantial... More
